INmune Bio, Inc. (NASDAQ:INMB) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET

Company Participants

David Moss – Co-Founder and Chief Financial Officer

RJ Tesi – Co-Founder and Chief Executive Officer

Mark Lowdell – Co-Founder and Chief Scientific Officer

Conference Call Participants

Tom Shrader – BTIG

William Wood – B. Riley

Daniel Carlson – TW Research Group

Operator

Greetings, and welcome to the INmune Bio Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.

At this time, it is my pleasure to introduce Mr. David Moss, Co-Founder and Chief Financial Officer of INmune Bio. David, the floor is yours.

David Moss

Thank you, Doug, and good afternoon everybody. We thank you for joining us for the call for INmune Bio’s second quarter 2022 financial results. With me on the call is Dr. RJ Tesi, CEO and Co-Founder of INmune Bio, who will provide a business update on our DN-TNF platform; and Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder, who will provide an update on our NK cell priming platform.

Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Act Reform of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statements disclaimer on the company’s earnings press release, as well as the risk factors in the company’s SEC filings, including our most recent quarterly filing with the SEC.

There’s no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as of the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information events or circumstances.

Now, I’d like to turn the call over to Dr. RJ Tesi, Co-Founder and CEO of INmune Bio. RJ?

RJ Tesi

Thank you, David, and thank you everyone for joining the call. As usual, I will arrange my remarks to highlight the key takeaways for the first quarter and subsequent period, and provide updates on our platform programs. I will review development of – developments in XPro then hand the call to Mark Lowdell, INmune Bio CSO, who will speak about recent developments in INKmune before David discusses financial results, upcoming milestones and we move to Q&A.